Boston Scientific Loses Share To J&J; Rebate Program Could Buoy Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's share of the U.S. drug-eluting stent market fell four percentage points to 55% during the third quarter as the firm failed to stop Johnson & Johnson/Cordis from stealing market share